ArticleFrontiers in genetics2025

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib.

Feng Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.